Q-omics provides the consensus-scored PCAT19 profile across patient tissues and cancer cell-line models. PCAT19 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PCAT19 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PCAT19 RNA expression shows 19,196 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KICH, and LSCC as cancer lineages where PCAT19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCAT19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCAT19 survival associations across molecular data types. PCAT19 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCAT19 RNA expression–survival associations across cancer types. High PCAT19 expression shows unfavorable associations in ACC, KIRP, UVM and MESO, but favorable associations in KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PCAT19 RNA expression.
This table summarizes PCAT19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PCAT19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCAT19 shows lower tumor expression in KICH, LUSC, LUAD, KIRP, THCA and UCEC. The KICH box plot shows higher PCAT19 RNA expression in normal versus tumor tissue (log2 FC = −1.704, t-test p < 0.001).
This table shows molecular features associated with PCAT19 in patient tissues and cancer cell lines. In patient samples, PCAT19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
